Endometrial cancer is the most common form of uterine cancer, arising from the endometrial lining of the uterus. Endometroid endometrial cancer is highly associated with increased estrogen levels, making it more common among young women, women with higher levels of body fat, and in those taking a form of exogenous estrogen.
In the 8MM, the diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 cases in 2030, at an Annual Growth Rate (AGR) of 1.06%. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed incident cases of endometrial cancer are expected to increase from 42,775 cases in 2020 to 47,947 cases in 2030, at an AGR of 1.21%. When examining the AGR by individual market, The publisher forecasts that all markets will see an increase in the diagnosed incident cases of endometrial cancer during the forecast period. As seen in Figure 2, in 2020, there were 483,737 five-year diagnosed prevalent cases of endometrial cancer in the 8MM, which is expected to increase to 547,783 cases by 2030, at an AGR of 1.32%.
Scope
Reasons to Buy this Report
The Endometrial Cancer Epidemiology series will allow you to:
In the 8MM, the diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 cases in 2030, at an Annual Growth Rate (AGR) of 1.06%. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed incident cases of endometrial cancer are expected to increase from 42,775 cases in 2020 to 47,947 cases in 2030, at an AGR of 1.21%. When examining the AGR by individual market, The publisher forecasts that all markets will see an increase in the diagnosed incident cases of endometrial cancer during the forecast period. As seen in Figure 2, in 2020, there were 483,737 five-year diagnosed prevalent cases of endometrial cancer in the 8MM, which is expected to increase to 547,783 cases by 2030, at an AGR of 1.32%.
Scope
- The Endometrial Cancer Epidemiology Report provides an overview of the risk factors and global trends of endometrial cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada)
- It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of endometrial cancer in these markets from 2020-2030. The incident cases are further segmented by age, International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis (I, II, IIIA, and IV), subtype (endometrioid, clear cell, serous, carcinosarcoma, and other), and associated biomarkers: microsatellite instability (MSI) high, mismatch repair deficiency (MMR-D), polymerase e (POLE ) ultra mutation, MSI hypermutated, copy number low (CN low), copy number high (CN high), programmed death-ligand 1 (PDL-1), and human epidermal growth factor receptor 2 (HER-2) positivity
- The endometrial cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM
Reasons to Buy this Report
The Endometrial Cancer Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global endometrial cancer market
- Quantify patient populations in the global endometrial cancer market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometrial cancer therapeutics in each of the markets covered
- Understand magnitude of endometrial cancer population by stage at diagnosis, subtypes, and mutations.
Table of Contents
1. Endometrial Cancer: Executive Summary
2. Epidemiology
3. Appendix
List of Tables
List of Figures
1. 8MM, Diagnosed Incident Cases of Endometrial Cancer, Women, Ages =18 Years, 2020 and 2030
